SCHEMBL19717166

SCHEMBL19717166

CCc1c(C#N)c(S)nc(N2CCC(N3CCCC3)CC2)c1C#N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.41
KDM4E B2RXH2 9/20 0.41
HPGD P15428 7/20 0.41
GAA P10253 4/20 0.41
DNMT1 P26358 1/20 0.39
PDCD1 Q15116 2/20 0.38
CD274 Q9NZQ7 2/20 0.38
MAPT P10636 1/20 0.38
HRH3 Q9Y5N1 4/20 0.37
HSD17B10 Q99714 2/20 0.36
HIF1A Q16665 2/20 0.36
RECQL P46063 1/20 0.36
POLB P06746 2/20 0.36
LMNA P02545 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
L3MBTL3 Q96JM7 1/20 0.34
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29658484 1.00 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL19734832 0.87 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL19717353 0.85 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL29658627 0.85 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL19734994 0.84 DNMT1 (0.53) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL19734950 0.81 DNMT1 (0.40) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL19717302 0.80 DNMT1 (0.38) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL29658560 0.80 DNMT1 (0.38) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL19734861 0.79 KDM4E (0.49) ALDH1A1KDM4EHPGDGAADNMT1
SCHEMBL19734698 0.78 KDM4E (0.54) ALDH1A1KDM4EHPGDMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 EP disclosed
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 CN disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 US disclosed
EP-3468953-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-04-17 EP disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B ALDH1A1 496/4885KDM4E 77/4885HPGD 3170/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B ALDH1A1 496/4885KDM4E 77/4885HPGD 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.